Observational studyRevista medica del Instituto Mexicano del Seguro Social2023
[ROX index to predict failure with low flow devices in COVID-19].
Observational study in Revista medica del Instituto Mexicano del Seguro Social, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The ROX index (iROX) obtained from pulse oximetry saturation/inspired fraction of oxygen and respiratory rate, predicts success with high-flow nasal cannula (HFNC), however its performance for low-flow oxygenation devices (DOBF) is unknown. Objective: To determine suitability of iROX at 12 hours as a predictor of mechanical ventilation (VMI) in hospitalized patients with severe COVID-19 and DOBF. Material and methods: An historical cohort was performed. Adults with COVID-19, hospitalized, with supplemental oxygen supply are included, excluding patients with pathologies in chronic stages that could alter the results, calculating the iROX at 12 hours, obtaining the cut-off point using a ROC curve and Youden index, the risk of VMI is prolonged using relative risk (RR), with 95% confidence intervals (95%CI). Confounding variables were evaluated to determine the performance of the iROX. The dependent variable mechanical ventilation recorded as reported in the file and the independent iROX obtained in the same way as the previous one. Results: 63 patients with a median age of 62 years were included. The best iROX cut-off point at 12 hours was 5.35. With this cut-off point, VMI was associated with a RR of 8.75 (95% CI 2.36-32.35). In the multivariate model with an OR of 9.26; (95% CI, 2.39 - 35.78), after initiation of DOBF was consistently associated with an increased risk of intubation. Conclusion: In hospitalized patients with severe COVID-19, an iROX < 5.35 at 12 hours appears to be a predictor for the onset of VMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.